Oversight of Clinical Trials in Europe - Member State perspective

Gunnar Danielsson
Senior Expert
Pharmaceutical Inspector

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Oversight of Clinical Trials

- **Oversight of clinical trials occur on many different levels:**
  - **Regulatory Agency approval**
  - **Ethics Committee approval**
  - **Inspections**
  - **Training and education**

Oversight of clinical trials and compliance with GCP standard provides public assurance that

- **the rights, safety and well-being of trial subjects are protected**
- **the clinical trial data are credible**

Trial subject

- **Declaration of Helsinki**
- **Ethics Committee/Regulatory Agency approval**
- **Confidentiality**
- **Informed consent**
- **Medical care and decisions by qualified physician**
- **Safety reporting**
- **Investigational Medicinal Product handling**

Data

- **Can we rely on the credibility of the data**

- **Application to Regulatory Authorities for permission to start clinical trails**
- **Clinical Trial Report**
- **Application to Regulatory Authorities to obtain registration (market authorization)**

Application to RA; by the sponsor

- **A fully completed and signed application form with unique Eudra-CT number**
- **Only one application for multicentre trials including list of all participating investigators**
- **All documents required for a valid application**
- **The application must be sent to the MPA electronically**

Application to RA; Documents needed

- **Signed cover letter**
- **Signed protocol including evaluation of the anticipated benefits and risks**
- **Adequate pre-clinical and clinical data including reference safety information for the assessment of the expectedness of any adverse reaction that might occur during the clinical trial**
- **IMPD and IMP-related information i.e. labelling, distribution**

Application process at MPA:



Application to Ethics Committee; by the Investigator

- **A fully completed and signed application form with unique Eudra-CT number**
- **Only one application for multicentre trials including list of all participating investigators**
- **All documents required for a valid application**
- **The application must be sent to the EC in paper format**

Application to Ethics Committee; Documents needed

- **Signed cover letter**
- **Signed protocol**
- **Investigator's Brochure or SmPC**
- **Information used during the study including patient information, informed consent, advertisment etc.**

Regulatory Agency versus Ethics Committee

- **The Ethics Committee review the impact of the protocol and clinical trial on the individual patient**

- **The Regulatory Agency review the impact of the protocol and clinical trial on the patient population**

Inspection strategy

- **Focus on achieving quality into the process in ongoing studies rather than finding faults in completed studies**

- **Focus on completed studies?**
  - **data driven**
- **Focus on ongoing studies?**
  - **process driven**

- **Inspection part of training and education**

Objects

- **App. 350-400 applications for clinical trials per year**
  - **app. 65 % sponsored**
  - **app. 35 % academic**
- **Divided on app. 2500 sites**
- **20-25 inspection per year**
- **Risk of inspection 1:100**

Inspection strategy

- **Mainly clinical sites**
- **Target all major pharmaceutical industries**
- **Small companies and academia ad hoc**
- **Networking with the academic organisations**
- **Education and training**

Education and training

- **Participate in external training activities i.e. academic institutions**
- **Participation in symposia and congresses**
- **Transparent activities via the internet**
- **Be available to respond to questions**

Lessons learned

- **Improved quality**
- **By doing few achieve a lot**
  - **cascade effect**
- **Awareness by being seen**
  - **small country – few players**
- **Accepted as a source of information**
  - **readily available**
  - **frequent contacts**
- **Appreciated by the pharmaceutical industry and academia**
  - **well-known and respected**
  - **communication and transparency**

Inspection site type vs number of inspections by EU Member States, 2000-2012



	No of Inspection
Q. Inspection Site Type	
CRO	437
Clinical Investigator	2,302
Laboratory	181
Not Answered	47
Not Specified	260
Other	406
Sponsor	572
Grand Total	**4,205**

GCP Inspections by European Authorities

Inspection outcome vs number of inspections by EU Member States



	No of Inspection
Q. Inspection Outcome	
No critical findings, no major findings	943
No critical findings, one or more major findings	2,257
Not Answered	49
Not Specified	109
One or more critical findings	847
Grand Total	**4,205**

GCP Inspections by European Authorities